Multikinase inhibitors in thyroid cancer

European Journal of Cancer

Volumn 46, Issue 6, 2010, Pages 1012-1018

  Licitra, Lisa ^a   Locati, Laura D ^a   Greco, Angela ^a   Granata, Roberta ^a   Bossi, P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Multikinase inhibitors; Thyroid cancer

Indexed keywords

AXITINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; E 7080; IMATINIB; MOTESANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROGLOBULIN; UNCLASSIFIED DRUG; VANDETANIB; XL 184;

ACUTE CHOLECYSTITIS; ARTICLE; HUMAN; HYPOTHYROIDISM; ONCOGENE; PRIORITY JOURNAL; THYROID CANCER;

BIOLOGICAL THERAPY; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS;

EID: 77949539631     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.010     Document Type: Article

References (72)

1. Reynolds R.M., Weir J., Stockton D.L., Brewster D.H., Sandeep T.C., and Strachan M.W. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 62 2 (2005) 156-162
2. Leenhardt L., Grosclaude P., and Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14 12 (2004) 1056-1060
3. Smailyte G., Miseikyte-Kaubriene E., and Kurtinaitis J. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer 6 December (2006) 284
4. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 18 (2006) 2164-2167
5. Liu S., Semenciw R., Ugnat A.M., and Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer 85 9 (2001) 1335-1339
6. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARC Press, Lyon
7. Sant M., Allemani C., Santaquilani M., Knijn A., Marchesi F., and Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45 6 (2009) 931-991
8. Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., and DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 9 (1985) 2155-2160
9. Sherman S.I. Thyroid carcinoma. Lancet 361 9356 (2003) 501-511
10. Cooper S.D., Doherty M.G., Bryan R., et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 11 (2009) 1167-1214 10.1089/thy.2009.0110
11. Smallridge R.C., Marlow L.A., and Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16 1 (2009) 17-44
12. Nucera C., Eeckhoute J., Finn S., et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res 15 11 (2009) 3680-3689
13. Lee D.H., Lee G.K., Kong S.Y., et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60 8 (2007) 881-884
14. Bongarzone I., Vigneri P., Mariani L., Collini P., Pilotti S., and Pierotti M.A. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4 1 (1998) 223-228
15. Santoro M., Carlomagno F., Hay I.D., et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89 5 (1992) 1517-1522
16. Fenton C.L., Lukes Y., Nicholson D., Dinauer C.A., Francis G.L., and Tuttle R.M. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85 3 (2000) 1170-1175
17. Bounacer A., Wicker R., Caillou B., et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15 11 (1997) 1263-1273
18. Rabes H.M., Demidchik E.P., Sidorow J.D., et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6 3 (2000) 1093-1103
19. Nikiforova M.N., and Nikiforov Y.E. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8 1 (2008) 83-95
20. Hubner R.A., and Houlston R.S. Molecular advances in medullary thyroid cancer diagnostics. Clin Chim Acta 370 1-2 (2006) 2-8
21. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 2 (2005) 245-262
22. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 10 (2009) 1675-1684
23. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 6 (2004) 855-867
24. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 11 (2003) 5399-5404
25. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 12 (2005) 6373-6379
26. Xing M., Clark D., Guan H., et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 20, 27 18 (2009) 2977-2982
27. Chuang T.C., Chuang A.Y., Poeta L., Koch W.M., Califano J.A., and Tufano R.P. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 32 2 (2010) 229-234
28. Melillo R.M., Castellone M.D., Guarino V., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115 4 (2005) 1068-1081
29. Garcia-Rostan G., Zhao H., Camp R.L., et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21 17 (2003) 3226-3235
30. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 7 (2003) 1454-1457
31. Xin X., Yang S., Ingle G., et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158 (2001) 1111-1120
32. Boccaccio C. Comoglio PM Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6 (2006) 637-645
33. Soh E.Y., Duh Q.Y., Sobhi S.A., et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82 11 (1997) 3741-3747
34. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 3 (2005) 11-16
35. Klein M., Vignaud J.M., Hennequin V., et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86 2 (2001) 656-658
36. Lennard C.M., Patel A., Wilson J., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 5 (2001) 552-558
37. Croyle M., Akeno N., Knauf J.A., Fabbro D., et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 1,68 11 (2008) 4183-4191
38. Rodriguez-Antona C., Pallares J., Montero-Conde C., et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17 1 (2010) 7-16
39. Hoffmann S., Glaser S., Wunderlich A., et al. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 391 6 (2006) 589-596
40. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 92 (2000) 205-216
41. Eisenhauer E.A., Therasseb P., Bogaertsc J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer 45 (2009) 228-247
42. Hong D.S., Reddy S.B., Prieto V.G., et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144 6 (2008) 779-782
43. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359 1 (2008) 31-42
44. Schlumberger M.J., Elisei R., Bastholt L., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol June (2009) 29
45. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 29 (2008) 4714-4719
46. de Groot J.W., Zonnenberg B.A., van Ufford-Mannesse P.Q., et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 9 (2007) 3466-3469
47. Wong E., Rosen L.S., Mulay M., et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17 4 (2007) 351-355
48. Kurzrock R, Sherman S, Pfister D, et al. Preliminary results of a phase 1 study of XL184, a MET, VEGFR2 and RET receptor tyrosine kinase inhibitor (TKI), administered orally to patients with thyroid cancer (TC). Presented at the World Congress on Thyroid Cancer, vol. 105. Abstract 0153, August 6-10; 2009.
49. Haddad R.I., Krebs A.D., Vasselli J., Paz-Ares L.G., and Robinson B. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26 20 Suppl. (2008) 322s
50. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. Am Soc Clin Oncol 25 18S (2007) 303s
51. Fox E., Widemann B.C., Whitcomb P.O., et al. Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. Curr Opin Oncol 27 15S (2009) 522S
52. Salgia R., Sherman S.I., Hong D.S., et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26 15S (2008) 158s
53. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26 29 (2008) 4708-4713
54. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomografy in metastatic gastrontestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of a new computed tomography response criteria. J Clin Oncol 13 (2007) 1753-1759
55. Crabb S.J., Patsios D., Sauerbrei E., et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 20, 27 3 (2009) 404-410
56. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27 10 (2009) 1675-1684
57. Giraudet A.L., Vanel D., Leboulleux S., et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92 11 (2007) 4185-4190
58. Cabanillas M.E., Waguespack S.G., Bonstein Y., et al. Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): the M.D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 27 15S (2009) 316s
59. V600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol 27 15S (2009) 301s
60. Flaherty K., Puzanov I., Sosman J., et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27 (2009) 461s
61. Schwartz G, Yazji S, Menedelson DS, et al. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients with advanced solid tumors. In: 20th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics. October 21-24, Geneva; 2008.
62. Frank-Raue K., Fabel M., Delorme S., Haberkorn U., and Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157 (2007) 215-220
63. Ha H.T., Lee J.S., Urba S., Koenig R.J., Sisson J., Giordano T., et al. Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC). J Clin Oncol 27 15S (2009) 315s
64. Ravaud A., de la Fouchardiere C., Courbon F., Asselineau J., Klein M., Nicoli-Sire P., et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26 15S (2008) 330s
65. Goulart B., Carr L., Martins R.G., Eaton K., Kell E., Wallace S., et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol 26 15S (2008) 331s
66. Carr L., Goulart B., Martins R.G., Keith E., Kell E., Wallace S., et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). J Clin Oncol 27 15S (2009) 315
67. Nagaiah G., Fu P., Wasman J.K., Cooney M.M., Mooney C., Afshin D., et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 27 15S (2009) 315s
68. Lam ET, Ringel MD, Kloos RT, et al., A phase II study of sorafenib in patients with metastatic medullary thyroid carcinoma. In: 2009 AACR Annual Meeting. Abstract 4513.
69. Kober F., Hermann M., Handler A., et al. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 25 18S (2007) 14065
70. Cohen EE, Kanagarajan J, Tinich C, Kunnavakkam R, Needless B, Ivy P, et al. Sunitinib in patients with radioactive iodine refractory and progressive differentiated thyroid cancer: a phase 2 study. Presented at the World Congress on Thyroid Cancer, vol. 60. Abstract 051, August 6-10, 2009.
71. Cohen E.E., Needles B.M., Cullen K.J., et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (2008) 26 [May 20 Suppl.; abstract 6025]
72. Kloos R.T., Ringel M.D., Michael V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27 10 (2009) 1675-1684